Compare Redwire Corporation (RDW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs TG Therapeutics Inc — how do they compare? Redwire Corporation trades at $10.7 (market cap $2.67B), while TG Therapeutics Inc trades at $54.77 (market cap $8.36B). The key difference: TG Therapeutics Inc is far larger — about 3.1× Redwire Corporation's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| RDW | TGTX | |
|---|---|---|
Market Cap | $2.67B | $8.36B |
Sector | Technology | Health |
52-Week High | $25.90 | $59.06 |
52-Week Low | $5.06 | $26.94 |
Enterprise Value | $2.21B | $8.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Redwire Corporation (RDW) trades at $11.23, up 6.65% today, with a bullish technical signal and strong analyst support. The stock shows improving revenue trends with 2026 projections reaching $426 million, though profitability remains challenged with negative margins. Recent news highlights strategic investments in phased-array technology and record backlog growth, while institutional interest is strong with BlackRock's $196.5 million position.
The outlook remains cautiously optimistic given 80% analyst buy ratings and a $12.17 price target, but significant risks persist including continued cash burn, execution challenges, and premium valuation. Investors face the tension between promising space/defense growth opportunities and the company's ongoing inability to achieve profitability despite revenue expansion.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
